Inspection delay yields ops duplication; Angel finds the right deal in England;

> Anika Therapeutics faces four months of operating duplicate facilities in Massachusetts, result of a delayed FDA inspection prior to equipment relocation. Anika release

> CMO Angel Biotechnology says it's close to finalizing a deal to expand its manufacturing base into England because it was unable to find the "right deal" in Scotland. Article

> Saudi Arabia's Shamla Pharmaceutical Industries, a partnership of three pharma companies has signed a deal to build a pharmaceutical factory at the Industrial Valley in King Abdullah Economic City. Story

> BioMarin Pharmaceutical is doubling its production capacity for both drug and trial-supply compounds. Article

> Drug sampling data gathered by Roger Bate at the American Enterprise Institute show that China is largely responsible for the fakes attributed to India. Story

> Baxter says short-term manufacturing delays have caused a shortage of premix nitroglycerin in dextrose. FDA drug shortage Listing

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.